๐๏ธ Verified NIH Record โข Updated 2024-12-09
PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function (NCT06729853)
A Phase 1, Open-Label, Parallel-Group, Single-Dose Adaptive Study to Evaluate the Safety and Pharmacokinetics of SAP-001 in Adult Subjects With Normal and Impaired Renal Function
๐ต Active, Not Recruiting Phase1 / Phase2 ๐ Investigational Drug / Biologic Sponsor: Shanton Pharma Pte. Ltd.
๐ฉบ Plain-English Summary (8th-Grade Level)
This is a multicenter, open-label, non-randomized, parallel-group, single-dose, 2-part, adaptive study in which up to approximately 32 adult subjects will be enrolled in one of 4 groups (8 subjects per group) with varying degrees of renal function.
Who can join: Review the eligibility criteria below.
Location: Genesis Clinical Research โ Tampa, Florida
Age range: 18 Years to 80 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (2 Sites)
- Genesis Clinical Research โ Tampa, Florida
- Nucleus Network Pty Ltd โ Saint Paul, Minnesota
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Gout
- Assessing the Role of the NLRP3 Inflammasome in Intercritical Gout โ Beverly Hills, California
- Gout in the ED and Improving Research Participation โ Birmingham, Alabama
- Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients โ Margate, Florida
- Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001. โ Sacramento, California
- Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301) โ Birmingham, Alabama
Explore by condition: All Gout clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.